Rakuten Investment Management Inc. Purchases Shares of 60,839 Thermo Fisher Scientific Inc. $TMO

Rakuten Investment Management Inc. acquired a new position in Thermo Fisher Scientific Inc. (NYSE:TMO) during the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor acquired 60,839 shares of the medical research company’s stock, valued at approximately $30,810,000.

Several other hedge funds have also bought and sold shares of the stock. Legacy Wealth Managment LLC ID lifted its holdings in shares of Thermo Fisher Scientific by 78.6% during the 1st quarter. Legacy Wealth Managment LLC ID now owns 50 shares of the medical research company’s stock worth $25,000 after acquiring an additional 22 shares during the last quarter. Kilter Group LLC bought a new position in Thermo Fisher Scientific in the second quarter valued at $25,000. Allied Private Wealth LLC purchased a new stake in Thermo Fisher Scientific during the second quarter valued at about $26,000. High Note Wealth LLC boosted its holdings in shares of Thermo Fisher Scientific by 170.6% in the 4th quarter. High Note Wealth LLC now owns 46 shares of the medical research company’s stock worth $27,000 after purchasing an additional 29 shares in the last quarter. Finally, JPL Wealth Management LLC bought a new position in shares of Thermo Fisher Scientific during the 3rd quarter valued at about $28,000. 89.23% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of analysts recently weighed in on the company. Morgan Stanley boosted their target price on Thermo Fisher Scientific from $620.00 to $650.00 and gave the stock an “overweight” rating in a research report on Friday, July 24th. Evercore set a $570.00 price target on shares of Thermo Fisher Scientific in a research note on Monday, July 6th. Royal Bank Of Canada boosted their price objective on shares of Thermo Fisher Scientific from $490.00 to $580.00 and gave the stock a “sector perform” rating in a report on Friday, July 24th. Wolfe Research initiated coverage on shares of Thermo Fisher Scientific in a report on Tuesday, June 2nd. They set an “outperform” rating and a $535.00 target price on the stock. Finally, HSBC cut shares of Thermo Fisher Scientific from a “buy” rating to a “hold” rating and decreased their target price for the stock from $670.00 to $540.00 in a research report on Wednesday, June 3rd. One investment analyst has rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and six have issued a Hold rating to the stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $619.41.

Insider Activity

In other news, COO Gianluca Pettiti sold 400 shares of the company’s stock in a transaction dated Monday, July 27th. The shares were sold at an average price of $565.00, for a total transaction of $226,000.00. Following the completion of the transaction, the chief operating officer directly owned 24,651 shares of the company’s stock, valued at approximately $13,927,815. This represents a 1.60% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Marc N. Casper sold 10,000 shares of the firm’s stock in a transaction dated Thursday, August 20th. The stock was sold at an average price of $629.27, for a total value of $6,292,700.00. Following the completion of the sale, the chief executive officer directly owned 123,925 shares in the company, valued at $77,982,284.75. The trade was a 7.47% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders sold 73,768 shares of company stock valued at $44,122,820. 0.33% of the stock is owned by corporate insiders.

Thermo Fisher Scientific Price Performance

Shares of Thermo Fisher Scientific stock opened at $621.87 on Friday. The company has a debt-to-equity ratio of 0.74, a current ratio of 1.55 and a quick ratio of 1.18. Thermo Fisher Scientific Inc. has a one year low of $435.27 and a one year high of $647.00. The business’s 50 day simple moving average is $558.64 and its two-hundred day simple moving average is $512.08. The stock has a market capitalization of $229.94 billion, a P/E ratio of 33.45, a price-to-earnings-growth ratio of 2.57 and a beta of 0.85.

Thermo Fisher Scientific (NYSE:TMO) last issued its earnings results on Thursday, July 23rd. The medical research company reported $6.03 earnings per share (EPS) for the quarter, topping the consensus estimate of $5.71 by $0.32. Thermo Fisher Scientific had a net margin of 15.04% and a return on equity of 17.09%. The firm had revenue of $11.99 billion for the quarter, compared to analysts’ expectations of $11.71 billion. During the same quarter last year, the business earned $4.28 earnings per share. The business’s revenue was up 10.5% on a year-over-year basis. Thermo Fisher Scientific has set its FY 2026 guidance at 24.930-25.330 EPS. Analysts forecast that Thermo Fisher Scientific Inc. will post 25.12 EPS for the current year.

Thermo Fisher Scientific Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Thursday, October 15th. Shareholders of record on Tuesday, September 15th will be issued a $0.47 dividend. This represents a $1.88 dividend on an annualized basis and a yield of 0.3%. The ex-dividend date of this dividend is Tuesday, September 15th. Thermo Fisher Scientific’s dividend payout ratio (DPR) is 10.11%.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.